Scroll

orlistat 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
gastrointestinal lipase inhibitors	1996	96829-58-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: orlistat tetrahydrolipstatin xenical alli tetrahydrolipastatin	A lactone derivative of LEUCINE that acts as a pancreatic lipase inhibitor to limit the absorption of dietary fat; it is used in the management of obesity. Molecular weight: 495.75 Formula: C29H53NO5 CLOGP: 8.94 LIPINSKI: 1 HAC: 6 HDO: 1 TPSA: 81.70 ALOGS: -6.73 ROTB: 23 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

orlistat
tetrahydrolipstatin
xenical
alli
tetrahydrolipastatin

A lactone derivative of LEUCINE that acts as a pancreatic lipase inhibitor to limit the absorption of dietary fat; it is used in the management of obesity.

Molecular weight: 495.75
Formula: C29H53NO5
CLOGP: 8.94
LIPINSKI: 1
HAC: 6
HDO: 1
TPSA: 81.70
ALOGS: -6.73
ROTB: 23

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.36	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	4	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	1 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	9.22 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	1 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
April 23, 1999	FDA	HOFFMANN LA ROCHE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Steatorrhoea	169.52	17.06	31	6114	468	63482409
Cerebral venous thrombosis	95.87	17.06	25	6120	2049	63480828
Thalamic infarction	71.35	17.06	15	6130	477	63482400
Drug interaction	68.77	17.06	97	6048	229034	63253843
Cholelithiasis	56.28	17.06	41	6104	43884	63438993
Abdominal pain	55.97	17.06	101	6044	293355	63189522
Rectal discharge	50.80	17.06	12	6133	654	63482223
Rectal haemorrhage	50.11	17.06	40	6105	48990	63433887
Crystal nephropathy	41.89	17.06	11	6134	925	63481952
Abdominal pain upper	37.95	17.06	70	6075	206374	63276503
Oxalosis	36.51	17.06	6	6139	46	63482831
Menopausal symptoms	35.28	17.06	12	6133	2449	63480428
Hyperoxaluria	34.88	17.06	7	6138	176	63482701
Kidney fibrosis	34.31	17.06	11	6134	1870	63481007
Jaundice	32.33	17.06	25	6120	29226	63453651
Slow response to stimuli	31.62	17.06	9	6136	1023	63481854
Haematochezia	31.50	17.06	32	6113	53512	63429365
Nephropathy	30.41	17.06	14	6131	6327	63476550
Virologic failure	30.35	17.06	10	6135	1852	63481025
Acute hepatic failure	27.85	17.06	19	6126	18308	63464569
Urine oxalate increased	26.83	17.06	6	6139	256	63482621
Renal tubular atrophy	24.82	17.06	7	6138	769	63482108
Crying	23.74	17.06	19	6126	23324	63459553
Oropharyngeal blistering	23.73	17.06	7	6138	902	63481975
Pancreatitis	23.00	17.06	26	6119	49029	63433848
Pregnancy on oral contraceptive	22.82	17.06	7	6138	1030	63481847
Muscle spasticity	22.72	17.06	18	6127	21776	63461101
Liver iron concentration abnormal	22.02	17.06	4	6141	58	63482819
Ear pain	21.99	17.06	22	6123	36096	63446781
Lactic acidosis	20.92	17.06	22	6123	38265	63444612
Vanishing bile duct syndrome	20.71	17.06	6	6139	726	63482151
Bradyphrenia	20.38	17.06	11	6134	6969	63475908
Nephrosclerosis	18.55	17.06	6	6139	1048	63481829
Circulatory collapse	18.45	17.06	16	6129	21922	63460955
Gallbladder disorder	18.45	17.06	15	6130	18827	63464050
Liver function test abnormal	18.39	17.06	23	6122	48158	63434719
Depressed mood	18.32	17.06	21	6124	40170	63442707
Alanine aminotransferase increased	17.55	17.06	34	6111	103736	63379141
Pancreatitis acute	17.38	17.06	17	6128	27149	63455728
Abortion spontaneous	17.18	17.06	22	6123	47173	63435704

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Nephropathy	44.50	24.87	14	1280	5903	34949734
Blood uric acid increased	41.54	24.87	15	1279	9609	34946028
Hyperoxaluria	29.59	24.87	5	1289	129	34955508
Coronary artery disease	25.46	24.87	18	1276	48287	34907350

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cerebral venous thrombosis	93.29	17.41	25	6427	2728	79735208
Steatorrhoea	91.96	17.41	20	6432	901	79737035
Cholelithiasis	70.23	17.41	47	6405	52617	79685319
Nephropathy	62.27	17.41	25	6427	9713	79728223
Hyperoxaluria	61.59	17.41	12	6440	311	79737625
Thalamic infarction	59.44	17.41	15	6437	1292	79736644
Crystal nephropathy	48.29	17.41	13	6439	1442	79736494
Drug interaction	47.51	17.41	104	6348	415079	79322857
Abdominal pain	46.18	17.41	99	6353	389470	79348466
Rectal discharge	40.38	17.41	10	6442	798	79737138
Abdominal pain upper	40.27	17.41	68	6384	223751	79514185
Menopausal symptoms	40.07	17.41	12	6440	1951	79735985
Oxalosis	39.38	17.41	7	6445	108	79737828
Kidney fibrosis	36.92	17.41	13	6439	3522	79734414
Urine oxalate increased	33.98	17.41	7	6445	242	79737694
Rectal haemorrhage	33.72	17.41	36	6416	76264	79661672
Ear pain	31.49	17.41	24	6428	32845	79705091
Slow response to stimuli	28.14	17.41	9	6443	1816	79736120
Renal tubular atrophy	28.00	17.41	9	6443	1847	79736089
Acute hepatic failure	26.70	17.41	21	6431	30092	79707844
Muscle spasticity	25.84	17.41	18	6434	21457	79716479
Vomiting	25.61	17.41	114	6338	665714	79072222
Crying	24.70	17.41	18	6434	23025	79714911
Jaundice	23.26	17.41	25	6427	53324	79684612
Liver iron concentration abnormal	22.73	17.41	4	6448	58	79737878
Pneumonia	22.18	17.41	13	6439	660233	79077703
Oropharyngeal blistering	21.36	17.41	6	6446	778	79737158
Pancreatitis	21.31	17.41	27	6425	68548	79669388
Pregnancy on oral contraceptive	20.92	17.41	6	6446	839	79737097
Death	19.23	17.41	11	6441	566503	79171433
Diverticulitis	19.11	17.41	21	6431	45915	79692021
Hepatic steatosis	18.81	17.41	19	6433	37719	79700217
Off label use	18.58	17.41	28	6424	907187	78830749
Gallbladder disorder	18.26	17.41	14	6438	19326	79718610
Bradyphrenia	17.89	17.41	11	6441	10629	79727307
Lip swelling	17.53	17.41	19	6433	40892	79697044
Sleep apnoea syndrome	17.52	17.41	18	6434	36460	79701476

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A08AB01	ALIMENTARY TRACT AND METABOLISM ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS Peripherally acting antiobesity products
FDA MoA	N0000009916	Lipase Inhibitors
FDA EPC	N0000175591	Intestinal Lipase Inhibitor
MeSH PA	D019440	Anti-Obesity Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D057847	Lipid Regulating Agents
CHEBI has role	CHEBI:65001	tributyrin esterase inhibitor
CHEBI has role	CHEBI:71476	fatty acid synthase inhibitors
CHEBI has role	CHEBI:74518	anti-obestic agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Obesity	indication	414916001	DOID:9970
Primary hyperoxaluria	contraindication	17901006	DOID:2977
Obstruction of bile duct	contraindication	30144000
Anorexia nervosa	contraindication	56882008	DOID:8689
Hepatic failure	contraindication	59927004
Bulimia nervosa	contraindication	78004001
Vitamin deficiency	contraindication	85670002
Hepatic necrosis	contraindication	87248009
Liver function tests abnormal	contraindication	166603001
Drug-induced hepatitis	contraindication	235876009
Malabsorption States	contraindication
Calcium Oxalate Renal Calculi	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.77	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Pancreatic triacylglycerol lipase	Enzyme	P16233	LIPP_HUMAN	INHIBITOR	IC50	8.90	IUPHAR	DRUG LABEL
Gastric triacylglycerol lipase	Enzyme	P07098	LIPG_HUMAN	INHIBITOR			CHEMBL	DRUG LABEL
Fatty acid synthase	Enzyme	P49327	FAS_HUMAN		IC50	5.33	CHEMBL
Sn1-specific diacylglycerol lipase alpha	Enzyme	Q9Y4D2	DGLA_HUMAN		IC50	8	CHEMBL
Sn1-specific diacylglycerol lipase beta	Enzyme	Q8NCG7	DGLB_HUMAN		IC50	7.22	CHEMBL
Abhydrolase domain-containing protein 16A	Enzyme	O95870	ABHGA_HUMAN		IC50	7.52	CHEMBL
Monoacylglycerol lipase ABHD12	Enzyme	Q8N2K0	ABD12_HUMAN		IC50	7.10	CHEMBL
Cannabinoid receptor 1	GPCR	P21554	CNR1_HUMAN		Ki	5.60	CHEMBL
Monoacylglycerol lipase ABHD6	Enzyme	Q9BV23	ABHD6_HUMAN		IC50	7.32	CHEMBL
Hepatic triacylglycerol lipase	Enzyme	P11150	LIPC_HUMAN		IC50	8.52	CHEMBL
Endothelial lipase	Enzyme	Q9Y5X9	LIPE_HUMAN		IC50	8.22	CHEMBL
Platelet-activating factor acetylhydrolase	Enzyme	Q13093	PAFA_HUMAN		IC50	7.30	CHEMBL
Lipoprotein lipase	Enzyme	P06858	LIPL_HUMAN		IC50	7.18	CHEMBL
Fatty-acid amide hydrolase 1	Enzyme		FAAH1_RAT		IC50	8	CHEMBL
Pancreatic triacylglycerol lipase	Enzyme		LIPP_PIG		IC50	6.66	CHEMBL
Sn1-specific diacylglycerol lipase alpha	Enzyme		DGLA_MOUSE		IC50	7.70	CHEMBL

External reference:

ID	Source
4021159	VUID
N0000148610	NUI
D04028	KEGG_DRUG
4021159	VANDF
C0076275	UMLSCUI
CHEBI:94686	CHEBI
CHEMBL175247	ChEMBL_ID
D000077403	MESH_DESCRIPTOR_UI
DB01083	DRUGBANK_ID
5277	IUPHAR_LIGAND_ID
6318	INN_ID
95M8R751W8	UNII
3034010	PUBCHEM_CID
226918	RXNORM
109396	MMSL
186669	MMSL
29932	MMSL
8088	MMSL
d04429	MMSL
007654	NDDF
116093009	SNOMEDCT_US
387007000	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
ALLI	HUMAN OTC DRUG LABEL	1	0135-0461	CAPSULE	60 mg	ORAL	NDA	17 sections
ALLI	HUMAN OTC DRUG LABEL	1	0135-0461	CAPSULE	60 mg	ORAL	NDA	17 sections
Xenical	HUMAN PRESCRIPTION DRUG LABEL	1	61269-460	CAPSULE	120 mg	ORAL	NDA	30 sections
Xenical	HUMAN PRESCRIPTION DRUG LABEL	1	61269-460	CAPSULE	120 mg	ORAL	NDA	30 sections
ORLISTAT	HUMAN PRESCRIPTION DRUG LABEL	1	61269-565	CAPSULE	120 mg	ORAL	NDA authorized generic	30 sections
ORLISTAT	HUMAN PRESCRIPTION DRUG LABEL	1	61269-565	CAPSULE	120 mg	ORAL	NDA authorized generic	30 sections